The tumor immunotherapy relied on the activation of the cGAS-STING pathway as tumor-derived DNA activates the tumor-infiltrating DCs (Woo et al., 2014), or tumor-derived cGAMP directly activates the STING pathway (Marcus et al., 2018), inducing the secretion of type I interferons and promoting tumor-specific antigen presentation and CTL activation (Chen et al., 2016; Du and Chen, 2018; Guan et al., 2021; Zhou et al., 2021). Here, STING1 is linked to neoplasm.